Bruker AV-NEO Console for 7T MRI

项目摘要/摘要 该应用程序要求为新的磁共振(MR)成像/光谱仪控制台提供部分资金 (Bruker AV Neo)，更换和升级我们目前在7T/30厘米口径磁共振系统上的控制台(购买了20台 几年前，使用共享仪器赠款)。它一直是小动物磁共振成像的“主力” 核心(SAMRIC)，但现在技术上过时了，供应商认识到它的过时，不再 支持它，导致维修变得越来越困难，因为缺乏部件。购买新游戏机将 结果：更好的质量，更高的空间分辨率，更快的成像速度(对有价值的麻醉小鼠的风险更小)， 能够进行许多新的实验(即，新的MR序列，这些序列在旧的序列上是不可行的 光谱仪)，并且用户组增加了对计划和执行纵向的可行性的信心 由于新控制台的服务和部件将从供应商处获得，因此将进行试验。目前，我们的大多数人 用户更喜欢使用配备最先进控制台的9.4T MR系统，这也是我们针对7T系统的目标。这个 然而，7T系统对于纪念斯隆·凯特林(MSK)的科学家来说是至关重要的，因为它是一种组合的MR-PET 仪器，提供MSK唯一临床前同时进行双模式磁共振和PET成像的能力 不能在9.4T系统上完成，因为孔径较小。7T的大口径也使我们能够 在进行正电子发射计算机断层扫描研究的同时，同时为多只小鼠(4)成像。这一独特的功能依赖于 MR-PET研究的8个主要用户和2个次要用户(10笔赠款)，以及3个主要用户(7笔赠款支持) 多个鼠标同时成像。代谢组(2名用户，3名赠款)和两个神经成像组 (2个用户，3个赠款)也依赖7T，因为在未来的研究中积累了大量的数据 都是谓词的，所以改用9.4T是不可行的。该系统也有一些独特之处，因为我们允许 来自MSK以外的调查人员使用我们的系统，使用适当的预防措施以避免传播感染 到不同的动物群体。来自曼哈顿至少5家机构的调查人员利用了这一点 并使用7T/30 cm系统。 在MSK，几乎所有的研究都集中在癌症生物学上--如何预防、检测、理解和治疗癌症， 而所有支持这一应用的研究(除了1项)都是以癌症为重点的。我们的长期目标是 支持这些众多的调查员(26名补助金，16名调查员)，并为他们提供最先进的空间和 代谢成像支持他们治疗高度恶性癌症的新药和治疗方法的研究 并加强结局和癌症护理。具体地说，我们支持广泛的实验，用新的反 癌症治疗学专注于增强其现有能力并测试癌症的新方法 关心。该MR系统支持的所有研究项目都是可翻译的，具有潜在的近期应用前景 应用于临床。尤其是它的双模式MR-PET活体成像模式，最新开发的 示踪剂和成像方法可以很容易地应用于我们的临床。

PROJECT SUMMARY/ABSTRACT This application requests partial funding for a new magnetic resonance (MR) imaging/spectrometer console (Bruker AV NEO), to replace and upgrade our current console on the 7T/30 cm bore MR system (purchased 20 years ago with a Shared Instrumentation Grant). It has been the “workhorse” for the Small Animal MR Imaging Core (SAMRIC), but is now technologically obsolete and the vendor, recognizing its obsolescence, no longer supports it, resulting in repairs becoming increasingly difficult due to lack of parts. Purchasing a new console will result in: better quality, higher spatial resolution, faster imaging (less risk to valuable anesthetized mice), the capability of doing many new experiments (i.e., new MR sequences, that are not feasible on the old spectrometer), and increased confidence by the user group that it is feasible to plan and perform longitudinal experiments since service and parts will be available from the vendor for the new console. Currently, most of our users prefer to use the 9.4T MR system with a state-of-the art console, which is our goal for the 7T system. The 7T system however, is critical for Memorial Sloan Kettering (MSK) scientists because it is a combined MR-PET instrument, providing MSK’s only preclinical simultaneous dual modal MR and PET imaging capability which cannot be done on the 9.4T system because of a smaller bore size. The large bore size of the 7T also allows us to image multiple mice (4) simultaneously while also doing PET studies. This unique capability is relied upon by 8 major users and 2 minor users for MR-PET studies (10 grants), and 3 major users (supported by 7 grants) for simultaneous multiple mouse imaging. The metabolism group (2 users, 3 grants) and two neuro imaging groups (2 users, 3 grants) also rely on the 7T because of the plethora of data accumulated upon which future studies are predicated, so switching to the 9.4T is not feasible. The system is also somewhat unique in that we allow investigators from outside MSK to use our system, using appropriate precautions to avoid spreading infections to different animal colonies. Investigators from at least 5 institutions in Manhattan have taken advantage of this and used the 7T/30 cm system. At MSK, almost all research focuses on cancer biology – how to prevent, detect, understand, and treat cancer, and all the studies (except 1) supporting this application, are cancer focused. Our long term objectives are to support these numerous investigators (26 grants, 16 investigators), and provide them state of the art spatial and metabolic imaging to support their investigations of novel drugs and treatments to treat highly malignant cancers and enhance outcome and cancer care. Specifically, we support a wide range of experiments with novel anti- cancer therapeutics focusing on enhancing their current capabilities and testing novel approaches to cancer care. All the research projects this MR system supports are translational with potential near future applications to clinical use. This is especially true for its dual modal MR-PET in vivo imaging modality where newly developed tracers and imaging methods can be readily applied in our clinics.